Shopping Cart
Remove All
Your shopping cart is currently empty
5-BDBD is a potent and selective P2X4 receptor antagonist. 5-BDBD inhibits rP2X4R-mediated currents with an IC50 of 0.75 μM. 5-BDBD completely blocked the basal and acute hyperalgesia induced by NTG.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $36 | In Stock | In Stock | |
| 2 mg | $52 | In Stock | In Stock | |
| 5 mg | $84 | In Stock | In Stock | |
| 10 mg | $147 | In Stock | In Stock | |
| 25 mg | $322 | In Stock | In Stock | |
| 50 mg | $572 | In Stock | In Stock | |
| 100 mg | $815 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $94 | In Stock | In Stock |
| Description | 5-BDBD is a potent and selective P2X4 receptor antagonist. 5-BDBD inhibits rP2X4R-mediated currents with an IC50 of 0.75 μM. 5-BDBD completely blocked the basal and acute hyperalgesia induced by NTG. |
| Targets&IC50 | P2X4:0.75 μM |
| In vitro | 5-BDBD could be specifically used to discriminate between P2X1R, P2X2aR, P2X2bR, P2X3R, P2X4R, and P2X7R[1]. 5-BDBD inhibits 10 μM ATP-induced currents of rP2X4R-expressing HEK293 cells in a concentration-dependent manner, with an IC50 of 0.75 μM[1]. 5-BDBD displaces rightward the ATP concentration-response curve, with an EC50 of 4.7 to 15.9 μM[1]. |
| In vivo | Basal hyperalgesia induced by recurrent NTG injection was completely blocked by 5-BDBD[2]. |
| Animal Research | 5-BDBD (28 mg/kg; i.p.; daily for 9 days; male C57BL/6 mice) prevented NTG-induced mechanical hypersensitivity[2]. |
| Molecular Weight | 355.19 |
| Formula | C17H11BrN2O2 |
| Cas No. | 768404-03-1 |
| Smiles | Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (168.92 mM), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.63 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.